These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20657835)

  • 1. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
    Kraft P; Schwarz T; Meijers JC; Stoll G; Kleinschnitz C
    PLoS One; 2010 Jul; 5(7):e11658. PubMed ID: 20657835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.
    Denorme F; Wyseure T; Peeters M; Vandeputte N; Gils A; Deckmyn H; Vanhoorelbeke K; Declerck PJ; De Meyer SF
    Stroke; 2016 Sep; 47(9):2419-22. PubMed ID: 27470988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.
    Orbe J; Alexandru N; Roncal C; Belzunce M; Bibiot P; Rodriguez JA; Meijers JC; Georgescu A; Paramo JA
    Thromb Res; 2015 Aug; 136(2):445-50. PubMed ID: 26118976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
    Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
    J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke.
    Kraft P; Schwarz T; Pochet L; Stoll G; Kleinschnitz C
    Exp Transl Stroke Med; 2010 Feb; 2(1):5. PubMed ID: 20298537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
    Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
    Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
    Mook-Kanamori BB; Valls Serón M; Geldhoff M; Havik SR; van der Ende A; Baas F; van der Poll T; Meijers JC; P Morgan B; Brouwer MC; van de Beek D
    J Thromb Haemost; 2015 Nov; 13(11):2076-86. PubMed ID: 26340319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
    Nagashima M; Yin ZF; Zhao L; White K; Zhu Y; Lasky N; Halks-Miller M; Broze GJ; Fay WP; Morser J
    J Clin Invest; 2002 Jan; 109(1):101-10. PubMed ID: 11781355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?
    Morser J; Gabazza EC; Myles T; Leung LL
    J Thromb Haemost; 2010 May; 8(5):868-76. PubMed ID: 20128866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
    Zhou X; Declerck PJ
    J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW; Goor MP; Guimaraes AH; Brouwers GJ; Maat MP; Dippel DW; Rijken DC
    J Thromb Haemost; 2005 Oct; 3(10):2211-8. PubMed ID: 16092924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
    Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
    Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model.
    Chessum JE; Shaya SA; Rajab D; Aftabjahani A; Zhou J; Weitz JI; Gross PL; Kim PY
    J Thromb Haemost; 2024 Jan; 22(1):263-270. PubMed ID: 37751849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.
    Renckens R; Roelofs JJ; ter Horst SA; van 't Veer C; Havik SR; Florquin S; Wagenaar GT; Meijers JC; van der Poll T
    J Immunol; 2005 Nov; 175(10):6764-71. PubMed ID: 16272333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).
    Bouma BN; Meijers JC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):13-9. PubMed ID: 14872415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
    Nagashima M; Yin ZF; Broze GJ; Morser J
    Front Biosci; 2002 Feb; 7():d556-68. PubMed ID: 11815293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFI.
    Hillmayer K; Macovei A; Pauwels D; Compernolle G; Declerck PJ; Gils A
    J Thromb Haemost; 2006 Nov; 4(11):2470-7. PubMed ID: 17002650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
    Qin L; D'Alessandro-Gabazza CN; Aoki S; Gil-Bernabe P; Yano Y; Takagi T; Boveda-Ruiz D; Ramirez Marmol AY; San Martin Montenegro VT; Toda M; Miyake Y; Taguchi O; Takei Y; Morser J; Gabazza EC
    J Thromb Haemost; 2010 Apr; 8(4):808-16. PubMed ID: 20088932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.
    Sillen M; Declerck PJ
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.